Description: Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Home Page: www.artelobio.com
505 Lomas Santa Fe
Solana Beach,
CA
92075
United States
Phone:
858 925 7049
Officers
| Name | Title |
|---|---|
| Mr. Gregory D. Gorgas M.B.A. | President, CEO, CFO, Treasurer, Secretary & Director |
| Dr. Andrew Yates Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. Steven D. Reich | Chief Medical Officer |
| Mr. Jason H. Baybutt | Senior Vice President of Finance |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | ? |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-06-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |